<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755378</url>
  </required_header>
  <id_info>
    <org_study_id>D1960C00001</org_study_id>
    <nct_id>NCT00755378</nct_id>
  </id_info>
  <brief_title>AZD8529 Single Ascending Dose Study</brief_title>
  <acronym>SAD</acronym>
  <official_title>Phase I, Single-Center, Randomized, Double-Blind, Placebo Controlled Single-Ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and PK of AZD8529 in Healthy Subjects Part B: A Randomized, Open Label Study to Assess the Effect of Food on AZD 8529</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate safety, tolerability, PK and PD effects of orally administered
      AZD8529 after single ascending doses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of single dose administration of AZD8529 when given orally to healthy male subjects and female subjects of non-childbearing potential.</measure>
    <time_frame>at each visit, at least daily, during the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of AZD8529 in plasma and urine.</measure>
    <time_frame>Blood and urine samples will be taken during the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To asses the effect of food on the safety and pharmacokinetic profile of AZD8529.</measure>
    <time_frame>Safety assessments and blood and urine samples will be taken throughout the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8529</intervention_name>
    <description>Oral</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects aged 18 to 45 years (inclusive) on Day 1. Female
             subjects must be of non-child bearing potential.

        Exclusion Criteria:

          -  Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) or has participated in any other clinical study that included
             drug treatment within 3 months of the first administration of investigational prod

          -  Plasma donation within one month of screening or any blood donation/blood loss &gt; 500mL
             during the 3 months prior to screening

          -  Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical
             chemistry, hematology or urinalysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvan J Hurewitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>March 25, 2009</last_update_submitted>
  <last_update_submitted_qc>March 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark A. Smith, MD</name_title>
    <organization>AStraZeneca</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

